当前位置： SCI文献检索 > ACS Medicinal Chemistry Letters期刊下所有文献 > Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response.

Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response.

Abstract：

:Cellular proteins that fail to fold properly result in inactive or disfunctional proteins that can have toxic functions. The unfolded protein response (UPR) is a two-tiered cellular mechanism initiated by eukaryotic cells that have accumulated misfolded proteins within the endoplasmic reticulum (ER). An adaptive pathway facilitates the clearance of the undesired proteins; however, if overwhelmed, cells trigger apoptosis by upregulating transcription factors such as C/EBP-homologous protein (CHOP). A high throughput screen was performed directed at identifying compounds that selectively upregulate the apoptotic CHOP pathway while avoiding adaptive signaling cascades, resulting in a sulfonamidebenzamide chemotype that was optimized. These efforts produced a potent and selective CHOP inducer (AC50 = 0.8 μM; XBP1 > 80 μM), which was efficacious in both mouse embryonic fibroblast cells and a human oral squamous cell cancer cell line, and demonstrated antiproliferative effects for multiple cancer cell lines in the NCI-60 panel.

journal_name

ACS Med Chem Lett

journal_title

ACS medicinal chemistry letters

authors

Flaherty DP,Miller JR,Garshott DM,Hedrick M,Gosalia P,Li Y,Milewski M,Sugarman E,Vasile S,Salaniwal S,Su Y,Smith LH,Chung TD,Pinkerton AB,Aubé J,Callaghan MU,Golden JE,Fribley AM,Kaufman RJ

doi

10.1021/ml5003234

subject

Has Abstract

pub_date

2014-10-29 00:00:00

pages

1278-1283

issue

12

issn

1948-5875

journal_volume

5

pub_type

杂志文章

相关文献

ACS Medicinal Chemistry Letters文献大全
  • GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis.

    abstract：:GPBAR1 agonists have been identified as potential leads for the treatment of diseases related to colon inflammation such as Crohn's and ulcerative colitis. In this paper, we report the discovery of a small library of hyodeoxycholane analogues, decorated at C-6 with different substituents, as potent and selective GPBAR...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.9b00636

    authors： Marino S,Finamore C,Biagioli M,Carino A,Marchianò S,Roselli R,Giorgio CD,Bordoni M,Di Leva FS,Novellino E,Cassiano C,Limongelli V,Zampella A,Festa C,Fiorucci S

    更新日期：2020-03-02 00:00:00

  • Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.

    abstract：:Activating mutations in the epidermal growth factor receptor (EGFR) have been identified in a subset of non-small cell lung cancer (NSCLC), which is one of the leading cancer types worldwide. Application of EGFR tyrosine kinase inhibitors leads to acquired resistance by secondary EGFR mutations or by amplification of ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml4003309

    authors： Szokol B,Gyulavári P,Kurkó I,Baska F,Szántai-Kis C,Greff Z,Orfi Z,Peták I,Pénzes K,Torka R,Ullrich A,Orfi L,Vántus T,Kéri G

    更新日期：2014-01-30 00:00:00

  • Structure-Based Virtual Screening for the Discovery of Novel Inhibitors of New Delhi Metallo-β-lactamase-1.

    abstract：:Bacterial resistance has become a worldwide concern after the emergence of metallo-β-lactamases (MBLs). They represent one of the major mechanisms of bacterial resistance against beta-lactam antibiotics. Among MBLs, New Delhi metallo-β-lactamase-1 NDM-1, the most prevalent type, is extremely efficient in inactivating ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.7b00428

    authors： Spyrakis F,Celenza G,Marcoccia F,Santucci M,Cross S,Bellio P,Cendron L,Perilli M,Tondi D

    更新日期：2017-11-26 00:00:00

  • Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.

    abstract：:Recently, the binding kinetics of a ligand-target interaction, such as the residence time of a small molecule on its protein target, are seen as increasingly important for drug efficacy. Here, we investigate these concepts to explain binding and proton blockage of rimantadine variants bearing progressively larger alky...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.7b00458

    authors： Drakopoulos A,Tzitzoglaki C,McGuire K,Hoffmann A,Konstantinidi A,Kolokouris D,Ma C,Freudenberger K,Hutterer J,Gauglitz G,Wang J,Schmidtke M,Busath DD,Kolocouris A

    更新日期：2018-01-29 00:00:00

  • Structure-based ligand design of novel bacterial RNA polymerase inhibitors.

    abstract：:Bacterial RNA polymerase (RNAP) is essential for transcription and is an antibacterial target for small molecule inhibitors. The binding region of myxopyronin B (MyxB), a bacterial RNAP inhibitor, offers the possibility of new inhibitor design. The molecular design program SPROUT has been used in conjunction with the ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml200087m

    authors： McPhillie MJ,Trowbridge R,Mariner KR,O'Neill AJ,Johnson AP,Chopra I,Fishwick CW

    更新日期：2011-07-29 00:00:00

  • F-18 Labeled RGD Probes Based on Bioorthogonal Strain-Promoted Click Reaction for PET Imaging.

    abstract：:A series of fluorine-substituted monomeric and dimeric cRGD peptide derivatives, such as cRGD-ADIBOT-F (ADIBOT = azadibenzocyclooctatriazole), di-cRGD-ADIBOT-F, cRGD-PEG5-ADIBOT-F, and di-cRGD-PEG5-ADIBOT-F, were prepared by strain-promoted alkyne azide cycloaddition (SPAAC) reaction of the corresponding aza-dibenzocy...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml500464f

    authors： Kim HL,Sachin K,Jeong HJ,Choi W,Lee HS,Kim DW

    更新日期：2015-02-06 00:00:00

  • Desmethyl Macrolides: Synthesis and Evaluation of 4,8,10-Tridesmethyl Cethromycin.

    abstract：:Antibiotic-resistant bacteria are emerging at an alarming rate in both hospital and community settings. Motivated by this issue, we have prepared desmethyl (i.e., replacing methyl groups with hydrogens) analogues of third-generation macrolide drugs telithromycin (TEL, 2) and cethromycin (CET, 6), both of which are sem...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml400337t

    authors： Wagh B,Paul T,Debrosse C,Klepacki D,Small MC,Mackerell AD Jr,Andrade RB

    更新日期：2013-11-14 00:00:00

  • Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors.

    abstract：:Purine-rich foods have long been suspected as a major cause of hyperuricemia. We hypothesized that inhibition of human concentrative nucleoside transporter 2 (hCNT2) would suppress increases in serum urate levels derived from dietary purines. To test this hypothesis, the development of potent hCNT2 inhibitors was requ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml500343r

    authors： Tatani K,Hiratochi M,Nonaka Y,Isaji M,Shuto S

    更新日期：2015-01-28 00:00:00

  • Consequences of Depsipeptide Substitution on the ClpP Activation Activity of Antibacterial Acyldepsipeptides.

    abstract：:The acyldepsipeptide (ADEP) antibiotics operate through a clinically unexploited mechanism of action and thus have attracted attention from several antibacterial development groups. The ADEP scaffold is synthetically tractable, and deep-seated modifications have produced extremely potent antibacterial leads against Gr...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.7b00320

    authors： Li Y,Lavey NP,Coker JA,Knobbe JE,Truong DC,Yu H,Lin YS,Nimmo SL,Duerfeldt AS

    更新日期：2017-10-19 00:00:00

  • Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR.

    abstract：:The identification and lead optimization of a series of pyridopyrimidinone derivatives are described as a novel class of efficacious dual PI3K/mTOR inhibitors, resulting in the discovery of 31. Compound 31 exhibited high enzyme activity against PI3K and mTOR, potent suppression of Akt and p70s6k phosphorylation in cel...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.8b00002

    authors： Yu T,Li N,Wu C,Guan A,Li Y,Peng Z,He M,Li J,Gong Z,Huang L,Gao B,Hao D,Sun J,Pan Y,Shen L,Chan C,Lu X,Yuan H,Li Y,Li J,Chen S

    更新日期：2018-02-27 00:00:00

  • Epimers Switch Galectin-9 Domain Selectivity: 3N-Aryl Galactosides Bind the C-Terminal and Gulosides Bind the N-Terminal.

    abstract：:A series of 3-deoxy-3-N-arylated-β-d-galactoside and -guloside derivatives have been synthesized by cesium fluoride/trimetylsilylaryl triflate-mediated benzyne generation and N-arylation of 3-deoxy-3-amino-β-d-galactosides and -gulosides, respectively. Evaluation as ligands to galectin-1, 2, 3, 4N (N-terminal domain),...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.9b00396

    authors： Mahanti M,Pal KB,Sundin AP,Leffler H,Nilsson UJ

    更新日期：2019-12-04 00:00:00

  • Multiple in Vitro Inhibition of HIV-1 Proteins by 2,6-Dipeptidyl-anthraquinone Conjugates Targeting the PBS RNA.

    abstract：:We recently reported a series of 2,6-dipeptidyl-anthraquinone conjugates (AQs) as Trans-Activation Response element (TAR) RNA-binding agents able to inhibit in vitro the HIV-1 nucleocapsid (NC) protein-mediated processes. Because NC is a highly adaptable nucleic acid chaperone assisting several crucial steps along rev...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.9b00682

    authors： Gamba E,Sosic A,Saccone I,Magli E,Frecentese F,Gatto B

    更新日期：2020-03-23 00:00:00

  • Identification and SAR of Glycine Benzamides as Potent Agonists for the GPR139 Receptor.

    abstract：:A focused high throughput screening for GPR139 was completed for a select 100K compounds, and new agonist leads were identified. Subsequent analysis and structure-activity relationship studies identified (S)-3-chloro-N-(2-oxo-2-((1-phenylethyl)amino)ethyl)benzamide 7c as a potent and selective agonist of hGPR139 with ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.5b00247

    authors： Dvorak CA,Coate H,Nepomuceno D,Wennerholm M,Kuei C,Lord B,Woody D,Bonaventure P,Liu C,Lovenberg T,Carruthers NI

    更新日期：2015-07-20 00:00:00

  • N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.

    abstract：:A series of N-(3-ethynyl-2,4-difluorophenyl)sulfonamides were identified as new selective Raf inhibitors. The compounds potently inhibit B-Raf(V600E) with low nanomolar IC50 values and exhibit excellent target specificity in a selectivity profiling investigation against 468 kinases. They strongly suppress proliferatio...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.5b00039

    authors： Li Y,Cheng H,Zhang Z,Zhuang X,Luo J,Long H,Zhou Y,Xu Y,Taghipouran R,Li D,Patterson A,Smaill J,Tu Z,Wu D,Ren X,Ding K

    更新日期：2015-03-18 00:00:00

  • Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140.

    abstract：:This report describes the discovery of RAD140, a potent, orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM). The characterization of RAD140 in several preclinical models of anabolic androgen action is also described. ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml1002508

    authors： Miller CP,Shomali M,Lyttle CR,O'Dea LS,Herendeen H,Gallacher K,Paquin D,Compton DR,Sahoo B,Kerrigan SA,Burge MS,Nickels M,Green JL,Katzenellenbogen JA,Tchesnokov A,Hattersley G

    更新日期：2010-12-02 00:00:00

  • Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

    abstract：:Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG levels are implicated in epigenetic alt...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.7b00421

    authors： Popovici-Muller J,Lemieux RM,Artin E,Saunders JO,Salituro FG,Travins J,Cianchetta G,Cai Z,Zhou D,Cui D,Chen P,Straley K,Tobin E,Wang F,David MD,Penard-Lacronique V,Quivoron C,Saada V,de Botton S,Gross S,Dang L,Y

    更新日期：2018-01-19 00:00:00

  • Structure-Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors.

    abstract：:EPAC proteins are therapeutic targets for the potential treatment of cardiac hypertrophy and cancer metastasis. Several laboratories use a tetrahydroquinoline analog, CE3F4, to dissect the role of EPAC1 in various disease states. Here, we report SAR studies with tetrahydroquinoline analogs that explore various functio...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.7b00358

    authors： Sonawane YA,Zhu Y,Garrison JC,Ezell EL,Zahid M,Cheng X,Natarajan A

    更新日期：2017-10-02 00:00:00

  • meso-Thiophenium Porphyrins and Their Zn(II) Complexes: A New Category of Cationic Photosensitizers.

    abstract：:A new category of cationic meso-thiophenium porphyrins are introduced as possible alternatives to the popular meso-pyridinium porphyrins. Combinations of cationic porphyrins bearing meso-2-methylthiophenium and meso-4-hydroxyphenyl moieties T2(OH)2M (A2B2 type) and T(OH)3M (AB3 type) along with their zinc(II) complexe...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.0c00266

    authors： Mazumdar ZH,Sharma D,Mukherjee A,Basu S,Shukla PK,Jha T,Sengupta D

    更新日期：2020-09-10 00:00:00

  • Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.

    abstract：:A new subseries of ROMK inhibitors exemplified by 28 has been developed from the initial screening hit 1. The excellent selectivity for ROMK inhibition over related ion channels and pharmacokinetic properties across preclinical species support further preclinical evaluation of 28 as a new mechanism diuretic. Robust ph...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml500440u

    authors： Walsh SP,Shahripour A,Tang H,Teumelsan N,Frie J,Zhu Y,Priest BT,Swensen AM,Liu J,Margulis M,Visconti R,Weinglass A,Felix JP,Brochu RM,Bailey T,Thomas-Fowlkes B,Alonso-Galicia M,Zhou X,Pai LY,Corona A,Hampton C,H

    更新日期：2015-05-07 00:00:00

  • Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.

    abstract：:ROMK, the renal outer medullary potassium channel, is involved in potassium recycling at the thick ascending loop of Henle and potassium secretion at the cortical collecting duct in the kidney nephron. Because of this dual site of action, selective inhibitors of ROMK are expected to represent a new class of diuretics/...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.6b00122

    authors： Tang H,Zhu Y,Teumelsan N,Walsh SP,Shahripour A,Priest BT,Swensen AM,Felix JP,Brochu RM,Bailey T,Thomas-Fowlkes B,Pai LY,Hampton C,Corona A,Hernandez M,Metzger J,Forrest M,Zhou X,Owens K,Tong V,Parmee E,Roy S,K

    更新日期：2016-05-12 00:00:00

  • Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300.

    abstract：:C646 inhibits the lysine acetyltransferases (KATs) p300 and CBP and represents the most potent and selective small molecule KAT inhibitor identified to date. To gain insights into the cellular activity of this epigenetic probe, we applied chemoproteomics to identify covalent targets of the C646 chemotype. Modeling and...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.5b00385

    authors： Shrimp JH,Sorum AW,Garlick JM,Guasch L,Nicklaus MC,Meier JL

    更新日期：2015-10-31 00:00:00

  • Discovery of Potent and Selective Leads against Toxoplasma gondii Dihydrofolate Reductase via Structure-Based Design.

    abstract：:Current treatment of toxoplasmosis targets the parasite's folate metabolism through inhibition of dihydrofolate reductase (DHFR). The most widely used DHFR antagonist, pyrimethamine, was introduced over 60 years ago and is associated with toxicity that can be largely attributed to a similar affinity for parasite and h...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.6b00328

    authors： Welsch ME,Zhou J,Gao Y,Yan Y,Porter G,Agnihotri G,Li Y,Lu H,Chen Z,Thomas SB

    更新日期：2016-09-17 00:00:00

  • Radiochemical Synthesis and Evaluation of 13N-Labeled 5-Aminolevulinic Acid for PET Imaging of Gliomas.

    abstract：:The endogenous amino acid, 5-aminolevulinic acid (5-ALA), has received significant attention as an imaging agent, including ongoing clinical trials for image-guided tumor resection due to its selective uptake and subsequent accumulation of the fluorescent protoporphyrin IX in tumor cells. Based on the widely reported ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.7b00311

    authors： Pippin AB,Voll RJ,Li Y,Wu H,Mao H,Goodman MM

    更新日期：2017-11-15 00:00:00

  • Structure-Guided Optimization of Replication Protein A (RPA)-DNA Interaction Inhibitors.

    abstract：:Replication protein A (RPA) is the major human single stranded DNA (ssDNA)-binding protein, playing essential roles in DNA replication, repair, recombination, and DNA-damage response (DDR). Inhibition of RPA-DNA interactions represents a therapeutic strategy for cancer drug discovery and has great potential to provide...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.9b00440

    authors： Gavande NS,VanderVere-Carozza PS,Pawelczak KS,Vernon TL,Jordan MR,Turchi JJ

    更新日期：2020-01-02 00:00:00

  • Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator.

    abstract：:The identification and optimization of the first activators of fast skeletal muscle are reported. Compound 1 was identified from high-throughput screening (HTS) and subsequently found to improve muscle function via interaction with the troponin complex. Optimization of 1 for potency, metabolic stability, and physical ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.7b00546

    authors： Collibee SE,Bergnes G,Muci A,Browne WF 4th,Garard M,Hinken AC,Russell AJ,Suehiro I,Hartman J,Kawas R,Lu PP,Lee KH,Marquez D,Tomlinson M,Xu D,Kennedy A,Hwee D,Schaletzky J,Leung K,Malik FI,Morgans DJ Jr,Morgan BP

    更新日期：2018-02-13 00:00:00

  • PAR2 Modulators Derived from GB88.

    abstract：:PAR2 antagonists have potential for treating inflammatory, respiratory, gastrointestinal, neurological, and metabolic disorders, but few antagonists are known. Derivatives of GB88 (3) suggest that all four of its components bind at distinct PAR2 sites with the isoxazole, cyclohexylalanine, and isoleucine determining a...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.6b00306

    authors： Yau MK,Liu L,Suen JY,Lim J,Lohman RJ,Jiang Y,Cotterell AJ,Barry GD,Mak JY,Vesey DA,Reid RC,Fairlie DP

    更新日期：2016-10-10 00:00:00

  • Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672.

    abstract：:We encountered a dilemma in the course of studying a series of antagonists of the G-protein coupled receptor CC chemokine receptor-2 (CCR2): compounds with polar C3 side chains exhibited good ion channel selectivity but poor oral bioavailability, whereas compounds with lipophilic C3 side chains exhibited good oral bio...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.8b00439

    authors： Yang MG,Xiao Z,Cherney RJ,Tebben AJ,Batt DG,Brown GD,Chen J,Cvijic ME,Dabros M,Duncia JV,Galella M,Gardner DS,Khandelwal P,Ko SS,Malley MF,Mo R,Pang J,Rose AV,Santella JB 3rd,Shi H,Srivastava A,Traeger SC,Wang

    更新日期：2019-01-16 00:00:00

  • Identification of Human Toll-like Receptor 2-Agonistic Activity in Dihydropyridine-Quinolone Carboxamides.

    abstract：:Using a multiplexed, reporter gene-based, high-throughput screen, we identified 9-fluoro-7-hydroxy-3-methyl-5-oxo-N-(pyridin-3-ylmethyl)-2,3-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-6-carboxamide as a TLR2 agonist. Preliminary structure-activity relationship studies on the carboxamide moiety led to the identification o...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.8b00540

    authors： Hu Z,Banothu J,Beesu M,Gustafson CJ,Brush MJH,Trautman KL,Salyer ACD,Pathakumari B,David SA

    更新日期：2018-12-20 00:00:00

  • Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors.

    abstract：:Structure-activity relationship translation offers an expeditious means for discovery of new active series. This approach was applied to discover tetrahydroisoquinoline (THIQ)-based steroidomimetic microtubule disruptors. The two A-ring elements of a three-point steroidal pharmacophore were incorporated into a THIQ-ba...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml200232c

    authors： Leese MP,Jourdan F,Dohle W,Kimberley MR,Thomas MP,Bai R,Hamel E,Ferrandis E,Potter BV

    更新日期：2012-01-12 00:00:00

  • Structure-Activity Relationship Studies of 3- or 4-Pyridine Derivatives of DS-6930.

    abstract：:Derivatization efforts were continued to discover backups for a potent selective PPARγ modulator, DS-6930. In this Letter, the replacement of 2-pyridine ring in DS-6930 with 3- or 4-pyridyl group is reported. As the introduction of substituents on the pyridine ring did not provide potent partial agonists, modification...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.8b00645

    authors： Shinozuka T,Tsukada T,Fujii K,Tokumaru E,Matsui Y,Wakimoto S,Ogata T,Araki K,Sawamura R,Watanabe N,Mori M,Tanaka J

    更新日期：2019-02-26 00:00:00